Free Trial

Cyclerion Therapeutics (CYCN) Competitors

Cyclerion Therapeutics logo
$3.11 -0.01 (-0.32%)
Closing price 02/18/2025 04:00 PM Eastern
Extended Trading
$3.16 +0.05 (+1.61%)
As of 02/18/2025 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CYCN vs. BRNS, ATHE, RAPT, INKT, QTTB, ESLA, ANVS, TPST, CASI, and ITRM

Should you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Barinthus Biotherapeutics (BRNS), Alterity Therapeutics (ATHE), RAPT Therapeutics (RAPT), MiNK Therapeutics (INKT), Q32 Bio (QTTB), Estrella Immunopharma (ESLA), Annovis Bio (ANVS), Tempest Therapeutics (TPST), CASI Pharmaceuticals (CASI), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry.

Cyclerion Therapeutics vs.

Cyclerion Therapeutics (NASDAQ:CYCN) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.

Barinthus Biotherapeutics' return on equity of -34.26% beat Cyclerion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion TherapeuticsN/A -55.32% -48.35%
Barinthus Biotherapeutics N/A -34.26%-29.30%

Cyclerion Therapeutics received 19 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote.

CompanyUnderperformOutperform
Cyclerion TherapeuticsOutperform Votes
34
58.62%
Underperform Votes
24
41.38%
Barinthus BiotherapeuticsOutperform Votes
15
100.00%
Underperform Votes
No Votes

In the previous week, Cyclerion Therapeutics and Cyclerion Therapeutics both had 1 articles in the media. Barinthus Biotherapeutics' average media sentiment score of 1.00 beat Cyclerion Therapeutics' score of -1.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cyclerion Therapeutics Negative
Barinthus Biotherapeutics Positive

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 36.1% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cyclerion Therapeutics has higher revenue and earnings than Barinthus Biotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$1.62M5.20-$5.26MN/AN/A
Barinthus Biotherapeutics$800K54.31-$73.35M-$1.49-0.72

Barinthus Biotherapeutics has a consensus target price of $5.17, indicating a potential upside of 378.40%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Barinthus Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cyclerion Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.82, meaning that its share price is 182% less volatile than the S&P 500.

Summary

Barinthus Biotherapeutics beats Cyclerion Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Cyclerion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYCN vs. The Competition

MetricCyclerion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.43M$6.91B$5.80B$9.22B
Dividend YieldN/A2.89%5.27%3.98%
P/E RatioN/A3.3518.7915.83
Price / Sales5.20352.99479.0583.70
Price / CashN/A75.6346.0538.28
Price / Book0.675.547.145.01
Net Income-$5.26M$164.55M$3.20B$220.98M
7 Day Performance-7.44%1.73%1.38%2.13%
1 Month Performance4.01%1.38%3.47%1.63%
1 Year Performance7.24%-0.12%20.17%16.41%

Cyclerion Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYCN
Cyclerion Therapeutics
0.9726 of 5 stars
$3.11
-0.3%
N/A+7.3%$8.43M$1.62M0.0030Negative News
BRNS
Barinthus Biotherapeutics
3.4984 of 5 stars
$1.01
-1.9%
$5.17
+411.6%
-57.0%$40.63M$800,000.00-0.68107Positive News
ATHE
Alterity Therapeutics
1.6042 of 5 stars
$4.62
+8.7%
$8.00
+73.2%
+101.5%$40.38MN/A0.0010Gap Up
RAPT
RAPT Therapeutics
4.3749 of 5 stars
$1.15
-0.9%
$9.56
+730.9%
-95.4%$40.20M$1.53M-0.4280News Coverage
Positive News
INKT
MiNK Therapeutics
2.6149 of 5 stars
$9.96
-11.0%
$65.00
+552.6%
+8.3%$39.44MN/A-2.5530
QTTB
Q32 Bio
2.7871 of 5 stars
$3.18
+1.0%
$29.86
+838.9%
N/A$38.73M$1.16M-0.2239
ESLA
Estrella Immunopharma
3.1566 of 5 stars
$1.07
-4.5%
N/A+27.7%$38.71MN/A-4.12N/AAnalyst Forecast
Positive News
Gap Up
ANVS
Annovis Bio
2.5931 of 5 stars
$2.71
-7.7%
$31.40
+1,057.0%
-76.2%$38.65MN/A-0.613Short Interest ↓
TPST
Tempest Therapeutics
3.1731 of 5 stars
$0.88
+0.3%
$21.67
+2,364.1%
-75.5%$38.37MN/A-0.5720High Trading Volume
CASI
CASI Pharmaceuticals
4.0547 of 5 stars
$2.47
+0.4%
$6.00
+142.9%
-56.4%$38.26M$33.88M-1.11180Gap Up
ITRM
Iterum Therapeutics
2.8348 of 5 stars
$1.39
-2.8%
$5.00
+259.7%
+0.7%$38.25MN/A-0.7010Short Interest ↓

Related Companies and Tools


This page (NASDAQ:CYCN) was last updated on 2/19/2025 by MarketBeat.com Staff
From Our Partners